Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions
Explore this paper's citation graph
Summary
A better information regarding the presence and the function of different ILCs and of the inhibitory checkpoints in pathological conditions may offer important clues for the development of new immune therapeutic strategies.
- Type
- article
- Published
- 2019-04-26
- Cited by
- 68
- References
- 116
- Access
- Open access
- OpenAlex
- https://openalex.org/W31105707
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:133604340
Keywords
Humanities, Physics, Philosophy
References
- A Soluble Form of Lymphocyte Activation Gene-3 (IMP321) Induces Activation of a Large Range of Human Effector Cytotoxic Cells
- Group 3 innate lymphoid cells (ILC3s): Origin, differentiation, and plasticity in humans and mice
- NK Cell Maturation and Peripheral Homeostasis Is Associated with KLRG1 Up-Regulation1
- Interleukin‐33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells
- Alternative splice variants of the human PD-1 gene.
- Up on the tightrope: natural killer cell activation and inhibition
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
- Interleukin-13 and its receptors in colorectal cancer (Review).
- Innate immune recognition and control of adaptive immune responses.
- The Transcription Factors T-bet and Eomes Control Key Checkpoints of Natural Killer Cell Maturation
- Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages.
- IL-25-responsive, lineage-negative KLRG1hi cells are multipotential “inflammatory” type 2 innate lymphoid cells
- The transcription factor GATA3 controls cell fate and maintenance of type 2 innate lymphoid cells
- Human natural killer cells.
- Development, differentiation and diversity of innate lymphoid cells
- TLR/NCR/KIR: Which One to Use and When?
- „Natural”︁ killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell
- DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes.
- Existence of a natural killer (NK) cell repertoire for (allo)antigen recognition: definition of five distinct NK-determined allospecificities in humans.
- NKp44, A Triggering Receptor Involved in Tumor Cell Lysis by Activated Human Natural Killer Cells, Is a Novel Member of the Immunoglobulin Superfamily
Cited by
- Functions of Group 2 Innate Lymphoid Cells in Tumor Microenvironment
- ILC2 Activation by Protozoan Commensal Microbes
- The Good and the Bad of Natural Killer Cells in Virus Control: Perspective for Anti-HBV Therapy
- NK Cell-Fc Receptors Advance Tumor Immunotherapy
- NK Cell-Based Immunotherapy for Hematological Malignancies
- Molecular characteristics and possible functions of innate lymphoid cells in the uterus and gut.
- Exploiting Human NK Cells in Tumor Therapy
- Immunoregulatory Sensory Circuits in Group 3 Innate Lymphoid Cell (ILC3) Function and Tissue Homeostasis
- WITHDRAWN: A novel bifunctional T regulatory cell engaging (BiTE) TGF-β1/PD-L1 fusion protein with therapeutic potential for autoimmune diseases
- The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology
- Moving towards personalized treatments of immune-related adverse events
- IL-12 regulates the expansion, phenotype, and function of murine NK cells activated by IL-15 and IL-18
- Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28
- Glucocorticoids and the cytokines IL-12, IL-15 and IL-18 present in the tumor microenvironment induce PD-1 expression on human Natural Killer cells.
- Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self.
- Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer
- NK cells and ILCs in tumor immunotherapy.
- Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review
- The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy
- Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways.
Related papers
No related papers recorded.